Abattis CEO - A Letter To Shareholders

Vancouver, BC / ACCESSWIRE / February 3, 2015 / Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX:ATTBF - News) (CSE:ATT), provides a letter to shareholder from William ("Bill") Fleming, Chief Executive Officer ("CEO").

Dear Fellow Shareholders:

As Abattis' CEO, and as a shareholder myself, I want to take this opportunity to thank you for your decision to become an investor and for your ongoing support as we continue to progressively build our company in the emerging multi-billion dollar cannabis industry.

I also want to take a moment to provide you with some additional information regarding some further perspective on the Company, the strengths of its Board and people, and our long-term goals and objectives.

I believe that anything really worth doing, whether in life or in business, requires persistence and perseverance. Staying the course means having the necessary foresight, financial and people capital and, most importantly, courage to stick to your plan.

I got involved with Abattis as a Board member and then as CEO because of my interests in marijuana botanical drug development and the role I see us taking in the propagation and breeding of distinctive cannabis for medicinal use of the plant. The future development of proprietary cannabis intellectual property (IP) platforms is not only one of my primary mandates, but will undoubtedly be one of the most substantial growth areas in this market sector.

I attribute our future success in our ongoing progress in unlocking the synergistic value of our assets to the dedication and tireless efforts of our exceptionally talented team, pedigree scientific research relationships and the ongoing support, guidance and commitment of our board of directors.

I have always believed that all companies need two things to be successful--great assets and great people. We are constantly looking to add world-class talent that share our mission, values and commitment to growth.

Abattis' unique assets have drawn world-class talent to the company who will create a myriad of future possibilities to grow our business. First and foremost, however, there is a lot of work yet to be done to maximize the value of our existing portfolio of business assets. I believe that 2015 will be a pivotal year for the company as we transition from acquiring, and investing to the alignment and ongoing vertical development of our core key business units that allow for quick revenue execution and generation.

I am encouraged about the future growth prospects for Abattis. We will continue to identify, qualify, invest, partner, innovate, launch new products and further build our brands in all of our business segments in Canada and the USA. The management team is firmly committed to growing the Company and delivering value for future customers, employees and shareholders. We will continue to manage the business in a prudent manner in order to maintain our competitive position. We remain focused on what we do best - providing botanical solutions for an emerging cannabis industry.

During the year ahead, I look forward to sharing with you our new milestones and accomplishments as we lead the Company through its next stage of growth.

I am grateful to you, our shareholders for the continued confidence and support you have shown as we continue our mission in driving sustainable, long-term growth and value for our shareholders. I hope you share our excitement about your company's path and the shared opportunity.

Warm Regards,

Image: https://www.thenewswire.com/client_files/tnwndSlcd_.png
Click Image To View Full Size

William (Bill) Fleming

Chief Executive Officer

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Bill Fleming"
Bill Fleming, CEO

For further information, contact the Company's at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

SOURCE: Abattis Bioceuticals Corp.